Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody.
(2023) Nature Communications — Vol. 14, n° 1, p. 1062 [1-12] (2023)
Files
2023_Nachit_Nat_Commun.pdf
Open Access - Adobe PDF
- 11.82 MB
Details
- Authors
- Abstract
- To date, a biopsy is mandatory to evaluate parenchymal inflammation in the liver. Here, we evaluated whether molecular imaging of vascular cell adhesion molecule-1 (VCAM-1) could be used as an alternative non-invasive tool to detect liver inflammation in the setting of chronic liver disease. To do so, we radiolabeled anti-VCAM-1 nanobody (Tc-cAbVCAM1-5) and used single-photon emission computed tomography (SPECT) to quantify liver uptake in preclinical models of non-alcoholic fatty liver disease (NAFLD) with various degree of liver inflammation: wild-type mice fed a normal or high-fat diet (HFD), FOZ fed a HFD and C57BL6/J fed a choline-deficient or -supplemented HFD. Tc-cAbVCAM1-5 uptake strongly correlates with liver histological inflammatory score and with molecular inflammatory markers. The diagnostic power to detect any degree of liver inflammation is excellent (AUROC 0.85-0.99). These data build the rationale to investigate Tc-cAbVCAM1-5 imaging to detect liver inflammation in patients with NAFLD, a largely unmet medical need.
- Affiliations
Citations
Nachit, M., Montemagno, C., Clerc, R., Ahmadi, M., Briand, F., Bacot, S., Devoogdt, N., Serdjebi, C., Ghezzi, C., Sulpice, T., Broisat, A., Leclercq, I., & Perret, P. (2023). Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody. Nature Communications, 14(1), 1062 [1-12]. https://doi.org/10.1038/s41467-023-36776-7 (Original work published 2023)